Vaccine development against tuberculosis before and after Covid-19

Area of Science:

• Immunology and Vaccinology
• Infectious Diseases
• Public Health

Background:

• The COVID-19 pandemic highlighted the critical role of infectious diseases and vaccine development in global health security.
• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading infectious cause of mortality, necessitating urgent development of effective interventions.
• The World Health Organization aims to end TB by 2030, underscoring the need for novel vaccines.

Purpose of the Study:

• To explore how advancements in COVID-19 vaccine research and development can inform and benefit the development of new TB vaccines.
• To outline potential strategies for TB vaccine research, considering both shared and unique challenges.
• To compare and contrast experiences from COVID-19 vaccine development and rollout with the TB vaccine pipeline.

Main Methods:

• Review of major vaccine platforms and widely applied COVID-19 vaccines.
• Description of vaccination regimes and specific challenges in TB vaccine research and development.
• Analysis of complex immune mechanisms underlying TB protection and pathology.
• Overview of TB vaccine candidates currently in clinical trials.
• Discussion of transferable lessons from COVID-19 vaccine development to TB vaccine research.

Main Results:

• COVID-19 vaccine development offers valuable insights into vaccine platforms, clinical trial design, and regulatory pathways.
• TB vaccine development faces unique hurdles, including complex immunology involving innate and acquired immune responses that require precise tuning.
• Several TB vaccine candidates are progressing through clinical trials, indicating active research efforts.

Conclusions:

• Leveraging experiences from the COVID-19 vaccine pipeline can accelerate TB vaccine research and development.
• Understanding the specific immunological challenges of TB is crucial for designing effective vaccines.
• A combination of shared strategies and tailored approaches is necessary to achieve the goal of ending TB.